Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene: A positive 2018, moving ahead with a strong portfolio
information fournie par Boursorama 20/03/2019 à 17:45

Transgene: A positive 2018, moving ahead
with a strong portfolio

* Clinical trials set to announce key data in 2019
* Invir.IO(TM) platform designed to deliver a new generation of oncolytic viruses has demonstrated promising preclinical data and is progressing to clinical stage
* Launch of myvacTM - our platform for highly innovative virus-based, individualized immunotherapy has already achieved multiple milestones translated into a strategic partnership with NEC
* Received $48 million in Tasly Biopharmaceuticals Co., Ltd. ('Tasly') shares through the sale of TG1050 and TG6002 rights to Tasly in Greater China
* Key financial elements:
- €8 million in net income in 2018 as a result of the Tasly deal
- €20 million revolving credit facility secured, using its Tasly shares as collateral
- Financial visibility extended until mid-2020

Conference call scheduled today at 6:30 p.m. CET (in English) (details at the end of this release)

Valeurs associées

TRANSGENE
0,8300 EUR Euronext Paris -0,60%
Le présent contenu est proposé par Boursorama. Cet article ou cette vidéo ne doivent en aucun cas s'apparenter à un conseil en investissement ou une recommandation d'acheter, de vendre ou de continuer à détenir un investissement. Boursorama ne saurait être tenue responsable d'une décision d'investissement ou de désinvestissement sur la base de cet article ou de cette vidéo.

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
CAC 40
8 027,92 +0,58%
SOITEC
159,4 +11,35%
Pétrole Brent
108,46 -2,22%
NANOBIOTIX
36,06 -6,29%
HAFFNER ENERGY
0,1469 +5,99%
Chargement...

Pages les plus populaires

L'offre BoursoBank